Two independent studies published in the journal Cell show that immune cells known as neutrophils, whose abundance in the microenvironment of tumors has traditionally been associated with poor patient prognosis, can play an important role in the success of cancer immunotherapies.
One study identifies a functional state assumed by neutrophils following immunotherapy—termed the Sellhi state—in which they become formidable agents of antitumor immunity in mouse models of lung and colon cancer.
“Our results demonstrate that neutrophils, which play an important role in battling microbial pathogens, can also be mobilized to fight cancer if they are appropriately engaged,” said the senior author.
The other study simultaneously discovered in a mouse model of melanoma that neutrophils are essential to the complete destruction of tumors during immunotherapies such as immune checkpoint blockade (ICB). Reflecting these findings, tumor samples from patients successfully treated with ICB were found to be teeming with neutrophils.
“Our study identified a unique subpopulation of neutrophils with anti-tumor activity,” said the senior author. “When activated by an experimental immunotherapy, this subpopulation kills cancer cells that have evolved to escape a key mechanism of immune recognition and so helps eliminate advanced melanoma tumors in mice.”
Most immunotherapies in use today, including ICB, primarily activate CD8+ T cells, which recognize and destroy cancer cells. Multiple immune cell types display a degree of plasticity, which can shift them from states that support tumor growth to those that eliminate tumors. A growing body of evidence from mouse studies suggests that neutrophils too display such functional dichotomy. Yet nuanced investigation of their behavior in tumors and during immunotherapy has long been neglected, in part due to the limitations of techniques researchers use to isolate and assay individual cells in such studies.
The authors found that in both mice and in human lung cancers, neutrophil numbers surge in tumors that respond to immunotherapy. They show in models of lung and colon cancer that, in responsive tumors, it is neutrophils in the Sellhi state that explode in number and that their expansion is essential to the success of immunotherapy.
"We found that if we block this therapy-elicited neutrophil response in mice, the benefits of immunotherapy are lost,” said the author.
The researchers show in this study that neutrophils pushed into a Sellhi state during effective immunotherapy bear this gene expression pattern. Their dissection of neutrophil activation in a mouse model of colon cancer reveals that it rests on three key pillars of anti-tumor immunity. It depends, specifically, on the production by related immune cells of a factor (IL12) that activates killer T cells, which in turn produce a signaling protein named interferon-ɣ, further stimulating immune responses and—crucially—enabling the Sellhi neutrophil response.
The other team was studying a different aspect of tumor immunology when they made their neutrophil discovery.
As tumors advance, their constituent cancer cells often evolve to stop producing antigens—protein fragments that betray disease to T cells and other immune cells—to escape immune targeting. The researchers had previously shown that a combination immunotherapy they’ve been developing could eliminate advanced melanoma tumors in a mouse model, apparently overcoming such immune evasion.
That combination involves a chemotherapy and a pair of experimental immunotherapies: an infusion of CD4+ T cells engineered to target a melanoma antigen, and treatment with antibodies that activate a molecule on T cells known as OX40. The latter therapy switches the CD4+ T cells, better known for orchestrating immune responses, into a cancer cell-killing mode while inactivating regulatory T cells that suppress immune responses.
In the current study, the authors explored the mechanisms by which their experimental therapy clears cancer cells that have evolved to escape T cell recognition using a mouse model devised for the study of antigenic heterogeneity.
Their analysis revealed that tumors in the mice were consistently infiltrated with activated neutrophils following immunotherapy, something they also saw in tumor samples from melanoma patients who had responded well to ICB therapy. Depleting neutrophils in the mice compromised the curative efficacy of the experimental therapy. They also show that these neutrophils contribute to tumor elimination in a model of colorectal cancer.
“Our findings reveal a previously unrecognized and essential role played by neutrophils in mopping up cancer cells that evade the T cell attack stimulated by immunotherapies,” said the author. “They reiterate the importance of other types of immune cells in the success of ICB and other immunotherapies that activate T cell responses to treat cancer.”
The researchers identified unique gene expression signatures and cell surface molecular markers in tumor-targeting neutrophils. Further, activated neutrophils that helped clear cancer cell variants that had eluded T cell recognition expressed high levels of an enzyme that drives production of nitric oxide and is associated with enhanced cell killing capability in neutrophils.
“Our studies have independently reached the same conclusion about the importance of neutrophil activity to the success of distinct immunotherapies in models of three different types of tumors,” noted the author. “This suggests we have discovered an important dimension of tumor immunology—one that, we hope, will pave the way for new treatment strategies and the improvement of existing immunotherapies against cancer.”
https://www.cell.com/cell/fulltext/S0092-8674(23)00225-8
https://www.cell.com/cell/fulltext/S0092-8674(23)00210-6
Essential role of neutrophils in immunotherapy
- 1,192 views
- Added
Latest News
Complete vascularization of…
By newseditor
Posted 28 Mar
Immune cells identified as…
By newseditor
Posted 28 Mar
TB blood test which could d…
By newseditor
Posted 27 Mar
Propionate supplementation…
By newseditor
Posted 27 Mar
Role of human Kallistatin i…
By newseditor
Posted 26 Mar
Other Top Stories
'Merlin' magic on peripheral nerve damage repair
Read more
Beta-arrestin-2 is an essential regulator of pancreatic beta-cell f…
Read more
Ion channel necessary for hormone and anti-obesity drug to suppress…
Read more
Exosome messages from fat cells to prevent diabetes
Read more
Mitochondria size and blood glucose control
Read more
Protocols
Spatial proteomics in neuro…
By newseditor
Posted 28 Mar
All-optical presynaptic pla…
By newseditor
Posted 23 Mar
Epigenomic tomography for p…
By newseditor
Posted 20 Mar
A mouse DRG genetic toolkit…
By newseditor
Posted 17 Mar
An optogenetic method for t…
By newseditor
Posted 13 Mar
Publications
A microfluidic platform int…
By newseditor
Posted 28 Mar
Salmonella manipulates macr…
By newseditor
Posted 28 Mar
BHLHE40/41 regulate microgl…
By newseditor
Posted 28 Mar
Balancing neuronal activity…
By newseditor
Posted 28 Mar
OSBP-mediated PI(4)P-choles…
By newseditor
Posted 28 Mar
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar